Clene
Yahoo Finance • 9 months ago
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
Clene Inc. Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy metabolites in multiple sclerosis and Parkinson’s disease with CNM-Au8® treatm... Full story
Yahoo Finance • 9 months ago
Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
LOS ANGELES, CA - (NewMediaWire) - December 12, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Clene (NASDAQ: CLNN), together with its w... Full story
Yahoo Finance • 10 months ago
Clene Among Grant Awardees Selected to Advance Scientific Research on ALS
LOS ANGELES, CA - (NewMediaWire) - November 14, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Clene, a company targeting the treatment... Full story
Yahoo Finance • 10 months ago
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8® in the RESCUE ALS open-label extension trialReported statistically significant long-... Full story
Yahoo Finance • 12 months ago
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totali... Full story
Yahoo Finance • 12 months ago
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: C... Full story
Yahoo Finance • 12 months ago
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on impro... Full story
Yahoo Finance • 12 months ago
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8® 30mg compared to PRO-ACT matched placebo over long-term follow-up, p=0.046Prolonged life with 59% decreased risk of dea... Full story
Yahoo Finance • last year
Clene to Present at Upcoming September Conferences
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improv... Full story
Yahoo Finance • last year
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
19.3 month significant survival difference for CNM-Au8® treated participants versus placebo 52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au8 treatment exposure without any identified safety signals... Full story
Yahoo Finance • last year
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8® in the HEALEY ALS Platform trial Announced publication of the results... Full story
Yahoo Finance • last year
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up SALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with... Full story
Yahoo Finance • last year
Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
Investment led by Vivo Capital with participation from SymBiosis, Acuta Capital Partners, AIGH Capital, Serrado Capital LLC, and other new biotech investors, with support from existing insiders $40 million underwritten public offering with... Full story
Yahoo Finance • last year
Clene Announces Pricing of $40 Million Public Offering
SALT LAKE CITY, June 16, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutioniz... Full story
Yahoo Finance • last year
Clene Announces Launch of Proposed Public Offering
SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutioniz... Full story
Yahoo Finance • last year
Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
CNM-Au8® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) Clene plans to discuss the totality of the survival and time-to-event results from the full CNM-Au... Full story
Yahoo Finance • last year
Clene to Participate in the Maxim Group Virtual Healthcare Conference
SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutioni... Full story
Yahoo Finance • last year
Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights
ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical SALT LAKE CITY, May 12, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries,... Full story
Yahoo Finance • last year
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutio... Full story
Yahoo Finance • 2 years ago
Clene Appoints Neurology Expert to Executive Team
SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutioni... Full story
